Global Stem Cell R&D Discussed in Most Recent Report Published at MarketPublishers.com

20 Dec 2011 • by Natalie Aster

Market Publishers Ltd informs that new GBI Research's Pharmaceuticals Industry report has been added to its catalogue:

Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D

The stem cell therapies market has tremendous market potential in future. GBI Research analysis suggests that high unmet need in some of the major chronic diseases and a strong stem cell pipeline in those indications will drive the market growth for stem cell therapies in future. The immense market potential will also result in boost to further research in the area. In addition, increasingly supprove regulatory environment and more investments into stem cell R&D will boost the market prospects in future.

In 2010, stem cell research in the disease areas of oncology, cardiovascular and CNS disorders accounted for half of the total funding received from National Institutes of Health (NIH). While oncology accounted for the highest funding of 21% of the total funding, cardiovascular and CNS followed with 18% and 11% share in the total funding received from NIH. This suggests that these three areas are the top three areas of research in stem cells. Other major areas that received significant NIH funding included genetic disorders and hematological disorders.

Published: November'11
Report Price: $3500 (Single User License)

Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta

In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound annual growth rate (CAGR) of 5.3% between 2002 and 2010. By 2017, the global pain management market is estimated to reach $35.1 billion, indicating a CAGR of 3.0% between 2010 and 2017. The major reason behind the decline in the growth rate is the decline in the annual cost of treating pain in different indications during 2010-2017. Although the market for management is highly competitive, blockbuster sales of Lyrica (pregabalin) and Cymbalta (duloxetine HCl) coupled with improved diagnosis of pain indications such as fibromyalgia and neuropathic pain are expected to drive the market in the future.

Lyrica (pregabalin) is the branded anticonvulsant product of Pfizer. Lyrica is indicated for the treatment of epilepsy, fibromyalgia and neuropathic pain. Lyrica, along with Neurontin (gabapentin), is the first line of therapy for the treatment of neuropathic pain, especially when tricyclic antidepressants are contraindicated. Lyrica is the only anticonvulsant which has been approved for the treatment of fibromyalgia. Lyrica generated revenue of $2.6 billion and $2.8 billion for Pfizer in 2008 and 2009 respectively. Eli Lilly’s Cymbalta is another major drug approved for fibromyalgia, chronic osteoarthritis pain and chronic low back pain. Cymbalta registered revenue of $2.6 billion and $3 billion in 2008 and 2009 respectively.

Published: November'11
Report Price: $3500 (Single User License)

More new market research reports by the publisher can be found at GBI Research page

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com